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Abstract: Inﬂ  ammatory processes are orchestrated by several soluble molecules, which interact 
with cell populations involved. Cytokines, chemokines, acute-phase reactants, and hormones 
are crucial in the evolution of several inﬂ  ammatory disorders, such as atherosclerosis. Several 
evidences suggest that C-reactive protein (CRP) started to be considered as a cardiovascular 
risk factor, since CRP directly induces atheroslerosis development. The recent demonstration 
of CRP production not only by the liver, but also within atherosclerotic plaques by activated 
vascular cells, also suggests a possible dual role, as both a systemic and tissue agent. Although 
more studies are needed, some therapeutic approaches to reduce CRP levels have been performed 
with encouraging results. However, given the strong limitations represented by its low speciﬁ  city 
and still accordingly with the American Heart Association, there is no need for high sensitivity 
CRP screening of the entire adult population as a public-health measure. The measure of serum 
CRP might be useful only for patients who are considered at intermediate risk.
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Introduction
Increasing evidence suggests a prominent role for inﬂ  ammatory processes in the 
pathogenesis of atherosclerosis (Hansson et al 2002; Hansson and Libby 2006). 
Inﬂ  ammatory cells and soluble mediators are key components of the atherosclerotic 
plaques in the different steps of lesion evolution (Worthley et al 2001; Root and 
Cobb 2004; Carter 2005). Therefore, although the causal factors of atherosclerosis 
remain unknown, inﬂ  ammation represents the main ﬁ  eld of investigations to identify 
new circulating biomarkers, capable of predicting plaque rupture and the consequent 
dramatic ischemic events, such as myocardial infarction or stroke. Several inﬂ  am-
matory agents, such as white blood cell count (Danesh et al 1998), cytokines (Ridker 
et al 2000b), chemokines (Aukrust et al 2001), and soluble adhesion molecules 
(Johnson et al 1997), have been studied without showing a sufﬁ  cient speciﬁ  city 
in predicting acute cardiovascular events. The low speciﬁ  city compared with the 
high cost of the tests represents one of strong limitation for their clinical use. Also 
further investigations are required to better understand the role of inﬂ  ammatory 
soluble mediators as cardiovascular risk markers or factors (Biomarkers Deﬁ  nitions 
Working Group 2001). In this context, C-reactive protein (CRP) has to be consid-
ered as the pivotal candidate to better characterize the cardiovascular risk. In fact, 
emerging evidence suggests that CRP is a pro-atherosclerotic factor with a causal 
role in atherogenesis. Furthermore, the recent demonstration of a double activity 
(in the blood stream and within arterial intima) supports CRP as both a predictor 
of cardiovascular risk and a possible therapeutic target for cardiovascular disease 
prevention (Koenig 2005). The present review provides an overview of the new Clinical Interventions in Aging 2008:3(2) 342
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evidences supporting the role of CRP in atherosclerotic 
inﬂ  ammatory processes.
Biological properties of CRP
CRP is a member of the pentraxin family of innate immune 
response proteins. It was ﬁ  rst described in 1930 by Tillet and 
Francis in the sera of patients suffering of pneumonia (Tillet 
and Francis 1930). The so called “fraction-C” precipitated 
when put in contact the C-polysaccharide of Streptococcus 
pneumoniae. The fraction-C, actually named CRP, is a 
nonglycosylated protein, composed by ﬁ  ve 23-kd subunits 
noncovalently associated and arranged symmetrically 
around a central pore (Thompson et al 1999). Furthermore, 
the half-life of CRP is about 19 hours and this does not 
change in healthy conditions or disease. For these reasons, 
elevated circulating levels of CRP in inﬂ  ammatory states 
are secondary to an increase of CRP production (Jialal et al 
2004). In healthy subjects, the CRP baseline concentration 
in the plasma is about 0.8 mg/l (Ford et al 2003a), and is 
in part genetically regulated (Tall 2004). Single nucleotide 
polymorphisms (SNPs) in both CRP gene and in a number 
of other genes regulating CRP secretion have been found 
associated with CRP baseline levels in humans (Eklund 
et al 2003; Chasman et al 2006; Lakka et al 2006; Sykora et al 
2006; Jakimiuk et al 2007; Osawa et al 2007; Shin et al 2007; 
Tang et al 2007; Walston et al 2007; Wong et al 2007; Zhang 
et al 2007b). Although still controversial, the modulation 
of CRP levels by other gene products might be considered 
as a very promising ﬁ  eld for future investigations. Further 
studies of larger samples are warranted to assess the deter-
mination of CRP levels by polymorphisms in other genes. In 
humans, the gene encoding CRP is mapped to chromosome 
1 (1q23-24) and consists of 2 exons. SNPs in the CRP gene 
promoter have been found associated to differences in base-
line serum CRP levels (Kovacs et al 2005; Szalai et al 2005). 
In addition, also polymorphic sequences in other portions 
of CRP gene have been identiﬁ  ed (Cao and Hegele 2000; 
Szalai et al 2002; Russell et al 2004; Miller et al 2005) and 
associated with immune-mediated diseases or interindividual 
variations of baseline CRP production (Miller et al 2005; 
Kathiresan et al 2006). A recent study by Kathiresan and 
co-workers (2006) showed that common triallelic CRP SNP 
contributed modestly to CRP baseline levels in Framingham 
Heart Study participants. Clinical characteristics resulted 
as the most important variables implicated in variations 
of CRP (Kathiresan et al 2006). This has been conﬁ  rmed 
by another study showing that the most common causes of 
CRP deﬁ  ciency are represented by liver failure or therapies 
affecting the acute-phase stimulus (Vermeire et al 2004). 
Therefore, SNPs in other genes and clinical conditions appear 
as implicated in the regulation of CRP baseline levels rather 
than SNPs in CRP gene. On the other hand, CRP secretion 
is increased by infections (bacterial, fungal, mycobacterial, 
or severe viral) (Du Clos and Mold 2004), tissue necrosis 
(Dominguez-Munoz and Malfertheiner 1993), trauma (Du 
Clos 2000), neoplasia (Mahmoud and Rivera 2002), and other 
inﬂ  ammatory disorders, including atherosclerosis (Lagrand 
et al 1999). In all of these clinical syndromes, serum levels 
of CRP are increased by liver production in response to 
a variety of inﬂ  ammatory cytokines, such as IL-6, tumor 
necrosis factor (TNF)-alpha (Bastard et al 2006) and IL-1 
(Vermeire et al 2004). In the last decades, it was assumed 
that exclusively hepatocytes were capable of producing CRP 
(Sun et al 2005). However, the detection of CRP deposits in 
other tissues (Sun et al 2005) suggested that other cell types 
should be capable of producing CRP. Different cell popula-
tions, localized both in the atherosclerotic plaque or other 
tissues, are capable of expressing (Kolb-Bachofen et al 1995; 
Dong and Wright 1996; Singh et al 2007) or secreting (Kuta 
and Baum 1986; Ikuta et al 1986; Calabró et al 2003) CRP. 
Although the quantities of CRP production between liver and 
other tissues are not comparable, a recent work showed that 
atherosclerotic plaques are capable of releasing CRP in the 
blood stream and modifying local blood CRP levels (Inoue 
et al 2005). Therefore, this evidence strongly supports CRP 
not only as an endocrine (systemic) inﬂ  ammatory marker, but 
also as a paracrine (local) pro-atherosclerotic factor.
Is CRP a cardiovascular risk marker 
or factor?
Numerous prospective epidemiologic studies showed that in 
healthy subjects serum CRP predicts myocardial infarction 
mortality (Ridker et al 2000a, 2002; Boekholdt et al 2006), 
peripheral vascular disease (Ridker et al 1998b, 2001), 
congestive heart failure (Cesar et al 2003; Vasan et al 2003), 
stroke (Ridker et al 1997, 1998a; Gussekloo et al 2000) and 
arrhythmias, including sudden cardiac death (Albert et al 
2002). A meta-analysis of 14 prospective long-term studies 
showed that after correction for age, smoking, cardiovascular 
risk factors, and indicators of socioeconomic status, CRP 
was strongly related to coronary heart disease (Danesh 
et al 2000). In these studies, CRP levels were not inﬂ  uenced 
by Helicobacter pylori, HIV seropositivity, or Chlamydia 
pneumoniae immunoglobulin (IgG) titres. Therefore, in 
this paper these data appeared to support CRP as a potent 
cardiovascular risk marker, unrelated to other chronic Clinical Interventions in Aging 2008:3(2) 343
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inﬂ  ammatory states, such as chronic infections. However, 
other studies showed that CRP serum levels are increased 
in autoimmune diseases and infections (Mendall et al 2000; 
Roivainen et al 2000; Park et al 2002). A more recent clinical 
study by Danesh and co-workers (2004) strongly reduced the 
impact of CRP as a predictor of cardiovascular events. The 
authors, after a meta-analysis of twenty-two prospective stud-
ies, concluded that CRP is a “relatively moderate” predictor 
of coronary heart disease. On the basis of these different 
results, CRP speciﬁ  city for cardiovascular diseases appears 
to be low and recommendations regarding its clinical use for 
predicting acute cardiovascular events require validation. 
On the other hand, the association between chronic inﬂ  am-
matory diseases (with high CRP levels) and increased risk 
of coronary heart diseases (Roivainen et al 2000; Park et al 
2002; Ridker et al 2001; Lowe et al 2001) suggests that CRP 
might be considered as a cardiovascular risk factor rather 
than marker. To summarize, high CRP serum levels are 
induced in several inﬂ  ammatory conditions and are not spe-
ciﬁ  c for atherosclerosis. However, once established at high 
levels, CRP increases the cardiovascular risk. On the basis 
of these still controversial evidences, the American Heart 
Association and Centers for Disease Control and Prevention 
recommended to use CRP as a risk marker for cardiovascular 
diseases in individual with a Framingham risk score between 
10% and 20% (Pearson et al 2003). This subgroup of patients 
may beneﬁ  t from high-sensitivity (hs)-CRP testing, mainly 
because physicians are often undecided about the treatment 
for a patient who is considered at intermediate risk. In this 
case, an hs-CRP test might tip the scale to help a physician 
deciding on moderate or more intensive prevention treatment. 
However, the use of hs-CRP is also limited by the presence of 
other concomitant inﬂ  ammatory diseases. Thus, the answer to 
the question “is there any role for its routine measurement?” 
is still “it depends” (Ben-Yehuda 2007). Further investiga-
tions are needed to better characterize CRP as a marker for 
improving cardiovascular risk stratiﬁ  cation.
CRP is a potential independent 
cardiovascular risk factor
In order to investigate the role of CRP in the immune 
response, several papers previously indicated that it is 
necessary to exclude possible pro-inﬂ  ammatory artefacts 
due to the contamination of CRP commercial preparations. 
Contaminants (mainly sodium azide, LPS or IgG fragments) 
have been shown to induce signiﬁ  cant pro-inﬂ  ammatory 
effects on several cell types (Han et al 2004; Van den Berg 
et al 2004; Taylor et al 2005; Pepys et al 2005; Nerurkar 
et al 2005). Although these limitations, several studies 
showed that CRP is capable of activating complement and 
binding lipoproteins (Rowe et al 1984) or lysophospholipids 
(Mori et al 1991), also generated after myocardial infarc-
tion (Van der Vusse et al 1994). This evidence suggested 
that CRP could be not only an innocent bystander marker, 
but also an active factor in immune response underlying 
atherosclerotic processes. A direct contribution of CRP 
to atherosclerosis has been suggested by both in vitro and 
in vivo experiences on different cell populations, such as 
endothelial cells, leukocytes and smooth muscle cells. CRP 
increases adhesion molecules expression, such as ICAM, 
VCAM, E-selectin in human umbilical vein endothelial 
cells (ECs) (Pasceri et al 2000). Furthermore, CRP reduces 
both protein and mRNA for endothelial nitric oxide synthase 
(eNOS) in human coronary artery endothelial cells (HAEC) 
(Venugopal et al 2002) and human venous ECs (Verma 
et al 2002b). On the contrary, inducible nitric oxide synthase 
(iNOS) activity was increased by CRP. The increase of 
adhesion molecules expression and iNOS activity and the 
reduction of eNOS clearly support the crucial role of CRP on 
endothelium activation. Further evidences also support CRP 
as endothelial dysfunction causal factor (Verma et al 2002a; 
Venugopal et al 2003; Devaraj et al 2003). Also monocyte-
macrophages are triggered by CRP for pro-atherosclerotic 
functions. High levels of CRP induce monocyte chemotaxis 
and differentiation (Torzewski et al 2000; Zhang et al 2006), 
cytokine production (Ballou and Lozanski 1992), integrin 
CD11b and chemokine receptor upregulation (Woollard 
et al 2002; Han et al 2004), monocyte-platelets aggregation 
(Danenberg et al 2007) and oxidized low density lipoprotein 
(LDL) uptake (Chang et al 2002) through the binding to Fc-γ 
receptor I (CD64) and II (CD32). These studies suggest a 
pro-atherosclerotic role of CRP mainly in early phases of 
atherogenesis. However, other researchers recently showed 
that CRP could be involved also in later stages of atheroscle-
rosis, by inducing both matrix metalloproteinase (MMP)-1 
and MMP-9 expression and collagenase activity in human 
monocyte-macrophages (Williams et al 2004; Nabata et al 
2007). The function of neutrophils is also modulated by 
CRP. Neutrophil N-formyl-methionyl-leucyl-phenylalanine 
(fMLP)-induced chemotaxis and superoxide production 
were both inhibited by CRP (Zhong et al 1998; Mortensen 
and Zhong 2000). CRP also modulates smooth muscle cell 
pro-atherosclerotic functions. CRP upregulates angiotensin 
type-1 receptor (AT1R) on smooth muscle cells and increases 
angiotensin II-induced smooth muscle cells migration and 
proliferation (Wang et al 2003). In vivo studies showed a Clinical Interventions in Aging 2008:3(2) 344
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possible direct role for CRP as a pro-atherosclerotic factor. 
The low importance of acute-phase proteins in animals 
represents a strong limitation in developing in vivo models. 
Mouse CRP is a trace protein with a concentration which not 
exceeded 2 mg/L even after an inﬂ  ammatory stimulus (Pepys 
and Hirschﬁ  eld 2003). Recently, an important study showed 
that transgenic apolipoprotein E (ApoE) deﬁ  cient mice, 
expressing high serum levels of human CRP (100 mg/L), 
develop an acceleration of atherosclerotic lesion formation 
in comparison with control 7-month-old male ApoE deﬁ  cient 
mice (Paul et al 2004). The strong limitation of this study 
was represented by the high levels of CRP in these mice, 
not comparable with CRP levels (1–10 mg/L) detected in 
humans with increased cardiovascular risk (Pearson et al 
2003). Given the role of CRP in inﬂ  ammatory processes 
in hypercholesterolemic rabbits (Asgary et al 2007; Zhang 
et al 2007a), these animals and also transgenic mice 
expressing rabbit CRP could represent a good in vivo model 
for studying CRP in atherosclerosis (Xia and Samols 1997; 
Jiang et al 2006). However, further investigations are needed 
to validate this experimental approach. Therefore, given the 
strong limitations due to a possible effect of contaminants of 
the commercial compounds and the controversies in genetic 
studies (human SNPs and transgenic animal models) (Miller 
et al 2005; Balistreri et al 2006; Eklund et al 2007; Pai et al 
2008), we can consider CRP as a potential independent pro-
atherosclerotic factor. Therefore, although further evidences 
are needed, a therapeutic approach to reduce vascular CRP 
pro-inﬂ  ammatory activities could represent a possible new 
target to inﬂ  uence the development of atherosclerosis.
Therapeutic strategies to reduce 
CRP levels
Given the physiopathological role of CRP in atherosclerotic 
pro-inﬂ  ammatory processes, lowering CRP serum levels and 
vascular CRP synthesis or deposition might bean interesting 
strategy to reduce cardiovascular risk. Although detection 
of vascular CRP deposit in vivo appears to be difﬁ  cult, 
cardiovascular screening programs are needed to identify 
and treat at least patients with high concentrations of serum 
CRP. Behavioral or pharmacologic interventions have been 
proposed to reduce CRP serum levels. Weight loss and the 
reduction of adiposity were showed to induce favorable 
changes in hsCRP level (Tchernof et al 2002; Esposito et 
al 2003; Kopp et al 2003). Regular physical activity, beside 
weight loss, was shown to reduce CRP serum levels in several 
studies (Geffken et al 2001; Wannamethee et al 2002; Ford 
2002; Abramson and Vaccarino 2002; Reuben et al 2003). 
This anti-inﬂ  ammatory effect was also found in subjects 
without cardiovascular diseases (LaMonte et al 2002; 
Church et al 2002). For this reason, physical activity could 
and should be considered as a very promising CRP lowering 
strategy to prevent cardiovascular diseases. On the other 
hand, cigarette smoking was found to increase CRP as well 
as other cardiovascular risk factors and markers (Bermudez 
et al 2002; Bazzano et al 2003). Smoking cessation could 
represent an interesting approach to reduce CRP serum levels, 
but studies focused on this aspect are needed. Concerning 
alcohol consumption, light alcohol intake rather than 
abstension or abuse is associated with lower cardiovascular 
mortality and lower CRP serum levels (Fuchs et al 1995; 
Albert et al 2003). The intake of various dietary factors, 
such as long-chain ω-3 polyunsaturated fatty acids, retinol, 
vitamin C, serum folate caroteoids and selenium was also 
found inversely associated to CRP serum levels (Pischon et al 
2003; Ford et al 2003b). However, further studies are needed 
in order to identify a possible causal role for these agents 
in regulating CRP production. On the other hand, several 
pharmacolagic molecules have been showed to reduce CRP 
levels. Lipid-modulating medications, including 3-hydroxy-
3-methylglutaryl coenzyme A reductase inhibitors (statins), 
ﬁ  brates and niacin, have been found to inﬂ  uence directly, 
beyond lipid lowering properties, inﬂ  ammatory serum factor 
levels (Blake and Ridker 2002; Melenovsky et al 2002; 
Kashyap et al 2002). Statins reduced CRP concentrations 
through a direct action on hepatocyte intracellular signalling 
pathways (Ridker et al 1999; Arnaud et al 2005). The role 
of LDL in statin induced CRP modulation is controversial. 
A recent study showed that changes in LDL correlates 
with changes in CRP levels (Ansell et al 2003). On the 
contrary, other evidence showed an independent relationship 
between these two factors (Ridker et al 1999). Therefore, 
further evidences are needed to better clarify the molecular 
mechanisms involved in statin-induced reduction of CRP 
serum levels. Both ﬁ  brates and niacin have been showed 
to reduced CRP serum levels and cardiovascular risk in 
hyperlipidemic patients (Grundy et al 2002; Després et al 
2003). However, the molecular mechanism involved remains 
unclear. Also aspirin and other anti-platelets agent protective 
activity might be dependent on CRP serum levels. Reduction 
of cardiovascular risk induced by aspirin, clopidogrel or 
abciximab treatment was higher in patients with elevated 
CRP levels (Ridker et al 1997; Chew et al 2001; Lincoff 
et al 2001). However, a direct activity of these pharmacologic 
agents on reducing CRP serum levels is still controversial 
(Ikonomidis et al 1999; Feldman et al 2001; Backes et al Clinical Interventions in Aging 2008:3(2) 345
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2004). Finally, anti-hyperglycemic agents have been showed 
to reduce CRP serum levels (Staels et al 1998; Haffner et al 
2002). Also in this case, the molecular mechanisms involved 
remain still not identiﬁ  ed. Surprisingly, recent clinical studies 
showed that thiazolidinediones induce an increase of acute 
cardiovascular outcomes (Lipscombe et al 2007; Nissen and 
Wolski 2007). Given these contrasting results, further studies 
are needed to clarify the role of CRP in patients treated with 
thiazolidinediones.
Conclusions
The present review shows recent experimental evidences to 
support CRP as a potential cardiovascular risk factor with 
direct activities in cardiovascular disease. Circulating levels 
of CRP and vascular CRP (localized within atherosclerotic 
plaques) could play a dual role as an endocrine and a para-
crine agent. The properties of CRP localized in arterial intima 
could also suggest an interesting hypothesis to clarify how 
in several studies CRP serum levels were not related to the 
cardiovascular risk. It is possible that CRP deposition within 
atherosclerotic plaque, rather than serum CRP levels can be 
involved in atherosclerotic processes (Figure 1). Although the 
last guidelines on cardiovascular diseases by the European 
Society of Cardiology do not support CRP as a marker of 
cardiovascular risk (Nissen and Wolski 2007; Rydén et al 
2007; Mancia et al 2007), the American Heart Association 
(AHA/CDC) suggests that the measurement of CRP dosage 
might be useful only when physicians are undecided about 
indications of treatment for patients who are considered at 
intermediate cardiovascular risk. In this case, hs-CRP test 
might tip the scale to help a physician on their decision to 
introduce more intensive treatment (Ridker et al 2007). Since 
for cardiovascular risk stratiﬁ  cation the determination of CRP 
levels between 1 and 10 mg/L is needed (Pearson et al 2003), 
the indicated test is hs-CRP measurement, which measures 
values under 10 mg/L (Libby and Ridker 2004). The AHA also 
suggests that there is no need for hs-CRP screening of the entire 
adult population as a public-health measure, mainly because 
we do not have enough evidence that treatment strategies based 
on hs-CRP levels improve survival or reduce cardiovascular 
complications. To clarify this ﬁ  nding, further prospective 
studied are needed (Tchernof et al 2002). Therefore, although 
the AHA experts identiﬁ  ed a subgroup of patients who may 
beneﬁ  t from hs-CRP testing, at present, for most patients the 
Figure 1 Role of C-reactive protein (CRP) in atherosclerotic processes. CRP is a cardiovascular risk factor with a possible dual pro-atherosclerotic activity as both an 
endocrine or paracrine molecule. Localization of CRP within unstable or ruptured plaques suggests a possible crucial role during acute atherosclerotic events.Clinical Interventions in Aging 2008:3(2) 346
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emphasis must remain on detection, treatment and control of 
the major cardiovascular risk factors indicated by The Fram-
ingham Study, with the inclusion of obesity.
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